Author(s)

Lamiae Amaadour^1*, Zineb Benbrahim¹, Nadia Benaicha², Fatima Zahra Elmrabet¹, Samia Arifi¹, Chakib Nejjari², Nawfel Mellas¹

¹Departement of Medical Oncology, Hassan II University Hospital, Fez, Morocco.
²Laboratory of Epidemiology and Biostatistics, Faculty of Medicine of Fez, Fez, Morocco.

Background: Tumor-related leukocytosis is a paraneoplastic syndrome that is encountered occasionally in the clinical course of patients with lung carcinoma. The aim of this study is to evaluate the prognostic significance of leucocytosis in patients with metastatic non small cell lung carcinoma. Methods: We retrospectively reviewed 205 cases of metastatic non small cell lung carcinoma diagnosed between January 2007 and December 2012 at the department of medical oncology, Hassan II University Hospital of Fez, Morocco. Clinical and laboratory data were collected including white blood cells at baseline. Leucocytosis was studied in relation to overall survival and progression free survival. Results: The frequency of leucocytosis was of 57.5%. Patients with leucocytosis had shorter overall survival (OS, p = 0.015) and disease-free survival (DFS, p < 0.0001) than those without leucocytosis. In multivariable analysis, patients with leucocytosis had a significantly greater risk of death and recurrence than those without leucocytosis. Conclusion: Leucocytosis was valuable for predicting the prognosis of patients with metastatic non small cell lung carcinoma.

Paraneoplastic Leucocytosis, NSCLC, Metastatic Stage, Survival

Amaadour, L. , Benbrahim, Z. , Benaicha, N. , Elmrabet, F. , Arifi, S. , Nejjari, C. and Mellas, N. (2017) Leucocytosis Predicts Survival in Metastatic Non Small Cell Lung Carcinoma Patients—A Retrospective Review of a Single Institution Data. Journal of Cancer Therapy, 8, 948-953. doi: 10.4236/jct.2017.811084.